Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

No impact of rifamycin selection on tuberculosis treatment outcome in HIV coinfected patients.

Singh R, Marshall N, Smith CJ, Reynolds CJ, Breen RA, Bhagani S, Cropley I, Hopkins S, Swaden L, Johnson MA, Lipman MC.

AIDS. 2013 Jan 28;27(3):481-4. doi: 10.1097/QAD.0b013e32835a67fb.

PMID:
23014518
2.

Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens.

Centers for Disease Control and Prevention (CDC)..

MMWR Morb Mortal Wkly Rep. 2002 Mar 15;51(10):214-5.

3.

A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. A single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis.

Schwander S, RĂ¼sch-Gerdes S, Mateega A, Lutalo T, Tugume S, Kityo C, Rubaramira R, Mugyenyi P, Okwera A, Mugerwa R.

Tuber Lung Dis. 1995 Jun;76(3):210-8.

PMID:
7548903
4.
5.

Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis.

Burman W, Benator D, Vernon A, Khan A, Jones B, Silva C, Lahart C, Weis S, King B, Mangura B, Weiner M, El-Sadr W; Tuberculosis Trials Consortium..

Am J Respir Crit Care Med. 2006 Feb 1;173(3):350-6. Epub 2005 Aug 18.

PMID:
16109981
6.

Tuberculosis and HIV co-infection: a practical therapeutic approach.

Breen RA, Swaden L, Ballinger J, Lipman MC.

Drugs. 2006;66(18):2299-308. Review.

PMID:
17181373
7.

Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.

Weiner M, Benator D, Burman W, Peloquin CA, Khan A, Vernon A, Jones B, Silva-Trigo C, Zhao Z, Hodge T; Tuberculosis Trials Consortium..

Clin Infect Dis. 2005 May 15;40(10):1481-91. Epub 2005 Apr 14.

PMID:
15844071
8.

Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use.

Nettles RE, Mazo D, Alwood K, Gachuhi R, Maltas G, Wendel K, Cronin W, Hooper N, Bishai W, Sterling TR.

Clin Infect Dis. 2004 Mar 1;38(5):731-6. Epub 2004 Feb 17.

PMID:
14986259
9.

Protease inhibitor-containing antiretroviral treatment and tuberculosis: can rifabutin fill the breach?

Loeliger A, Suthar AB, Ripin D, Glaziou P, O'Brien M, Renaud-Thery F, Crowley S, Williams B, Ridzon R, Granich R, Gilks C.

Int J Tuberc Lung Dis. 2012 Jan;16(1):6-15. doi: 10.5588/ijtld.10.0626. Epub 2011 Aug 3. Review.

PMID:
21819645
11.

Moxifloxacin for the treatment of HIV-associated tuberculosis in patients with contraindications or intolerance to rifamycins.

Bonora S, Mondo A, Trentini L, Calcagno A, Lucchini A, Di Perri G.

J Infect. 2008 Jul;57(1):78-81. doi: 10.1016/j.jinf.2008.05.005. Epub 2008 Jun 11.

PMID:
18550175
12.

Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins.

Regazzi M, Carvalho AC, Villani P, Matteelli A.

Clin Pharmacokinet. 2014 Jun;53(6):489-507. doi: 10.1007/s40262-014-0144-3. Review.

PMID:
24777631
13.

Treatment outcome of HIV-associated tuberculosis in a resource-poor setting.

Ifebunandu NA, Ukwaja KN, Obi SN.

Trop Doct. 2012 Apr;42(2):74-6. doi: 10.1258/td.2011.110421.

PMID:
22431822
14.

TB drugs interact adversely with protease inhibitors.

[No authors listed]

AIDS Alert. 1996 Oct;11(10):117-8.

PMID:
11363854
15.

Frequency, severity and duration of immune reconstitution events in HIV-related tuberculosis.

Burman W, Weis S, Vernon A, Khan A, Benator D, Jones B, Silva C, King B, LaHart C, Mangura B, Weiner M, El-Sadr W.

Int J Tuberc Lung Dis. 2007 Dec;11(12):1282-9.

PMID:
18229435
16.

[The tolerability and therapeutic efficacy of rifabutin in the treatment of pulmonary tuberculosis].

Parola D, Dell'Orso D, Giovagnoli S, Bianconi S, Terzano C.

Recenti Prog Med. 1999 May;90(5):254-7. Italian.

PMID:
10380552
17.

Anti-HIV agents. Once-daily anti-HIV therapy in people co-infected with TB.

[No authors listed]

TreatmentUpdate. 2004 Apr-May;16(3):4-5. No abstract available.

PMID:
17219607
18.

Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis.

Khan FA, Minion J, Pai M, Royce S, Burman W, Harries AD, Menzies D.

Clin Infect Dis. 2010 May 1;50(9):1288-99. doi: 10.1086/651686. Review.

PMID:
20353364
19.

Updated guidelines for the use of rifamycins in HIV/TB-coinfected patients.

del Rio C.

AIDS Clin Care. 2004 Oct;16(10):85. No abstract available.

PMID:
15526395
20.

Drug-resistant tuberculosis treatment complicated by antiretroviral resistance in HIV coinfected patients: a report of six cases in Lesotho.

Satti H, McLaughlin MM, Seung KJ.

Am J Trop Med Hyg. 2013 Jul;89(1):174-7. doi: 10.4269/ajtmh.13-0046. Epub 2013 May 13.

Supplemental Content

Support Center